FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older Gallery FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older 维梧新闻 FDA Approves Arcutis’ ZORYVE™ (Roflumilast) Cream 0.3% For the Treatment of Plaque Psoriasis in Individuals Age 12 and Older 2022-08-03 13:49:10 08月 03日, 2022 | 阅读更多
Serán Bioscience Announces Investment by Vivo Capital Gallery Serán Bioscience Announces Investment by Vivo Capital 维梧新闻 Serán Bioscience Announces Investment by Vivo Capital 2022-03-11 16:21:32 03月 11日, 2022 | 阅读更多
VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China Gallery VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China 维梧新闻 VISEN Pharmaceuticals Closes $150 Million Series B Financing to Accelerate the Development and Commercialization of its Innovative Endocrinology Therapies in Greater China 2022-03-09 14:40:55 03月 09日, 2022 | 阅读更多
Vivo Capital Appoints New Managing Partners and Partners Gallery Vivo Capital Appoints New Managing Partners and Partners 维梧新闻 Vivo Capital Appoints New Managing Partners and Partners 2022-03-09 14:39:52 03月 09日, 2022 | 阅读更多
Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B Gallery Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B 维梧新闻 Vivo Capital’s Portfolio Company, Preventice was Bought by Boston Scientific for $1.2B 2022-03-09 14:39:09 03月 09日, 2022 | 阅读更多
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders Gallery Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders 维梧新闻 Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders 2022-03-09 14:38:19 03月 09日, 2022 | 阅读更多